Celecoxib: new indication. Ankylosing spondylitis: no pain justifies the use of a cox-2 inhibitor. Patients still exposed to unjustified risks.
D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D017277:Drug Approval; D005602:France; D006801:Humans; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*
D016861:Cyclooxygenase Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides